pretickt

Is IEX a good stock to buy?

IDEX Corporation · end-of-day data as of Nov 13, 2026

IDEX
IEX · $17.45B
$237.63-0.2%
Nov 13, 2026 · close
$220$230$240SepOctNov9:3016:003 months +1.8%Nov 13 · close
▲ 6
  • PT$257.55 +8.4%
  • ConsensusBuy · 15
  • News
  • Trendbullish
  • MAs4 of 4
  • MACD0.38
Neutral
  • Earnings in82d
  • P/E33.0x
  • RSI55
  • Support-4.2%
  • Resistance+0.1%
  • Off 52w high-2.5%
  • Volume0.6x
  • Bollingerupper half
  • FCF yield+3.8%
  • P/E vs own+9.9%
  • 52w range$161–$244
  • ATR+2.6%
  • Off ATH-3.5%
  • InsidersNone in 90d
  • MA20×50↓ in ~16d
▼ 2
  • P/E vs sector+20.6%
  • Sector▼ -11.7%

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is IDEX a good stock to buy?

IDEX is strong on 3 of the 5 questions about the business. The price is high: 33.0 times its earnings, above its 3-year median of 28.5 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand steady
  2. Advantage hard to copy
  3. Economics profits steady
  4. Execution delivers
  5. Fragility sturdy
  6. Price expensive
DemandDo people want more of what it sells?steady

IEX sales growth revenue growth

+3%a year, for the last 3 years

IDEX's sales grew 3% a year for 3 years, to $3.46B in fiscal 2025.

IEX analysts' forecast revenue estimates

+8%the sales they expect next fiscal year, on the last

Analysts expect IDEX's sales to grow 8% to $3.72B in fiscal 2026 (11 analysts).

IEX competitors

pretickt analysis+7%its sales in 12 months, on a year before

IDEX's sales grew 7% in the 12 months to Sep 30, 2026, faster than Lennox (+2%) and Xylem (+2%), slower than Symbotic (+21%) and Nordson (+7%).

IEX sales by business revenue by segment

43%of its sales from Health And Science Technologies

Health And Science Technologies brought IDEX 43% of its sales in fiscal 2025; Fluid And Metering Technologies 35%.

Advantage moatIs it hard to copy?hard to copy

IEX margin on each sale gross margin

45%left after making the product

IDEX kept 45% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 36%.

EconomicsDoes it make good money?profits steady

IEX cash generated free cash flow

$667Mcash left after investing, last 12 months

IDEX generated $667M of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.

IEX profit per share

-4%in its last fiscal year

IDEX's earnings per share fell 4% in fiscal 2025, to $6.41.

ExecutionDoes it deliver what it promises?delivers

IEX earnings vs estimates

8 of 8quarters above the analysts' estimate

IDEX beat the analysts' profit estimate in each of its last 8 quarters, the latest on Oct 28, 2026.

IEX insider selling

-$3.4Msold, net, by its executives in 12 months

IDEX's executives and directors sold a net $3.4M of shares in the 12 months to Nov 13, 2026; none bought.

IEX number of employees

-3%fewer people in a year

IDEX had 8,700 employees at the end of fiscal 2025, 3% fewer than a year before.

IEX CEO pay

$9.11Mfor fiscal 2025, 71% of it in stock and options

IDEX paid its CEO $9.11M for fiscal 2025, 71% of it in stock and options.

Fragility risksCould something break it?sturdy

IEX financial health Altman Z-score

5.7Altman Z-score, safe above 3

IDEX's Altman Z-score is 5.7 (Nov 13, 2026), above 3, where the safe zone starts.

IEX quality checks Piotroski score

8 of 9checks passed

IDEX passes 8 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on the current ratio.

IEX biggest customers

under 10%of sales from any one customer

No customer made 10% of IDEX's sales in fiscal 2025.

IEX in past recessions

pretickt analysis-11%its sales in the worst one

IDEX's sales fell in each of the last 2 US recessions, by as much as 11% in fiscal 2009.

Price valuationIs the price reasonable?expensive

IEX price vs profit P/E ratio

33.0×a year's earnings

IDEX's P/E ratio is 33.0 (Nov 13, 2026), above its 3-year median of 28.5.

IEX price vs competitors

pretickt analysis33.0×a year's earnings, against its competitors

Investors pay 33.0 times IDEX's earnings (Nov 13, 2026), more than for Nordson (32.8), Xylem (20.8) and Lennox (16.3), less than for Symbotic (376.1).

IEX analysts' target price target

+8%to their average target

Analysts' average price target for IDEX is $258, 8% above the Nov 13, 2026 close of $237.63.

IEX growth priced in fair value

pretickt analysis+11%a year, for ten years, to be worth the price

At $237.63 a share, IDEX's free cash flow must grow about 11% a year for ten years to be worth the price (Nov 13, 2026).

What is IDEX's P/E ratio?

IDEX's P/E ratio is 33.0 (Nov 13, 2026), above its 3-year median of 28.5. Investors pay 33.0 times IDEX's earnings (Nov 13, 2026), more than for Nordson (32.8), Xylem (20.8) and Lennox (16.3), less than for Symbotic (376.1).

Who are IDEX's biggest competitors?

pretickt compares IDEX with Nordson, Symbotic, Xylem and Lennox. IDEX's sales grew 7% in the 12 months to Sep 30, 2026, faster than Lennox (+2%) and Xylem (+2%), slower than Symbotic (+21%) and Nordson (+7%).

Are insiders selling IDEX stock?

IDEX's executives and directors sold a net $3.4M of shares in the 12 months to Nov 13, 2026; none bought.

How does IDEX make money?

Health And Science Technologies brought IDEX 43% of its sales in fiscal 2025; Fluid And Metering Technologies 35%.

How many employees does IDEX have?

IDEX had 8,700 employees at the end of fiscal 2025, 3% fewer than a year before.

Who are IDEX's biggest customers?

No customer made 10% of IDEX's sales in fiscal 2025.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.